The estimated Net Worth of David Jin is at least $1.45 Thousand dollars as of 10 July 2024. David Jin owns over 500 units of Avenue Therapeutics Inc stock worth over $1,450 and over the last 2 years David sold ATXI stock worth over $0.
David has made over 3 trades of the Avenue Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently David bought 500 units of ATXI stock worth $3,750 on 10 July 2024.
The largest trade David's ever made was buying 35,928 units of Avenue Therapeutics Inc stock on 10 February 2023 worth over $30,180. On average, David trades about 5,918 units every 84 days since 2022. As of 10 July 2024 David still owns at least 500 units of Avenue Therapeutics Inc stock.
You can see the complete history of David Jin stock trades at the bottom of the page.
David's mailing address filed with the SEC is C/O FORTRESS BIOTECH, INC., 1111 KANE CONCOURSE SUITE 301, BAY HARBOR ISLANDS, FL, 33154.
Over the last 7 years, insiders at Avenue Therapeutics Inc have traded over $3,169,091 worth of Avenue Therapeutics Inc stock and bought 867,969 units worth $1,169,423 . The most active insiders traders include Lindsay A Md Rosenwald, Michael S Weiss, and Robert L Davidow. On average, Avenue Therapeutics Inc executives and independent directors trade stock every 87 days with the average trade being worth of $210,758. The most recent stock trade was executed by Robert L Davidow on 11 December 2023, trading 617,000 units of ATXI stock currently worth $86,380.
avenue therapeutics, inc. (nasdaq: atxi), a fortress biotech (nasdaq: fbio) company, is a specialty pharmaceutical company focused on the development and commercialization of intravenous (iv) tramadol for the management of moderate to moderately severe postoperative pain. iv tramadol may fill a gap in the acute pain market between iv acetaminophen/nsaids and iv conventional narcotics. avenue is currently evaluating iv tramadol in a pivotal phase 3 program for the management of postoperative pain.
Avenue Therapeutics Inc executives and other stock owners filed with the SEC include: